Table 2.

HR and 95% CI for quartiles of energy-adjusted dietary acrylamide intake and risk of total RCC in the full cohorts and among never-smokers, and risk of fatal RCC and clear cell RCC in the full cohorts

Men (HPFS)Women (NHS)
# CasesSimple HR (95% CI)aMultivariable HR (95% CI)b# CasesSimple HR (95% CI)aMultivariable HR (95% CI)b
Total RCC
Full cohort
  Quartile 1661.00 (ref.)1.00 (ref.)821.00 (ref.)1.00 (ref.)
  Quartile 2861.32 (0.95–1.82)1.32 (0.95–1.84)870.94 (0.69–1.27)0.93 (0.69–1.27)
  Quartile 3681.04 (0.73–1.46)1.01 (0.71–1.43)961.02 (0.76–1.38)1.01 (0.75–1.36)
  Quartile 4721.21 (0.86–1.70)1.09 (0.77–1.55)720.87 (0.63–1.19)0.85 (0.61–1.17)
  Ptrend0.540.960.470.39
Never-smokers
  Quartile 1251.00 (ref.)1.00 (ref.)391.00 (ref)1.00 (ref.)
  Quartile 2301.16 (0.68–2.00)1.24 (0.72–2.14)421.01 (0.65–1.57)1.00 (0.64–1.55)
  Quartile 3331.37 (0.80–2.34)1.42 (0.83–2.44)411.08 (0.69–1.68)1.07 (0.68–1.67)
  Quartile 4341.63 (0.96–2.78)1.59 (0.93–2.72)291.06 (0.65–1.73)1.05 (0.64–1.71)
  Ptrend0.060.090.760.79
Fatal RCC
Full cohort
  Quartile 1161.00 (ref.)1.00 (ref.)241.00 (ref.)1.00 (ref.)
  Quartile 2241.68 (0.89–3.19)1.71 (0.90–3.25)190.81 (0.44–1.49)0.79 (0.43–1.45)
  Quartile 3201.51 (0.77–2.94)1.48 (0.76–2.90)210.93 (0.51–1.68)0.89 (0.49–1.61)
  Quartile 4242.02 (1.06–3.85)1.82 (0.94–3.52)231.13 (0.63–2.02)1.09 (0.60–1.97)
  Ptrend0.050.130.590.68
Clear cell RCC
Full cohort
  Quartile 1381.00 (ref.)1.00 (ref.)581.00 (ref.)1.00 (ref.)
  Quartile 2531.36 (0.89–2.07)1.34 (0.87–2.04)610.91 (0.64–1.31)0.92 (0.64–1.33)
  Quartile 3421.04 (0.67–1.62)0.98 (0.62–1.53)590.88 (0.61–1.27)0.88 (0.61–1.27)
  Quartile 4461.25 (0.81–1.94)1.09 (0.70–1.70)540.92 (0.63–1.34)0.92 (0.63–1.35)
  Ptrend0.560.910.660.67
  • aStratified by age in months and calendar time.

  • bAdditionally adjusted for BMI (<23, 23–<25, 25–<27, and ≥27 kg/m2), history of hypertension (yes and no), history of diabetes (yes and no), smoking status (analyses including smokers only; never, former/quit >10 years ago, former/quit ≤10 years ago, and current), pack-years (analyses including smokers only; continuous), duration of nonaspirin nonsteroidal anti-inflammatory drug use (<5 years and ≥5 years), energy intake (continuous), alcohol consumption (quartiles), and parity (NHS only; 0, 1–2, 3, and ≥4 children).